Immunotherapy, quite effective in other types of cancer, is malorezultativnoy in the treatment of pancreatic cancer. Tumor around allocates a protective layer of cells and proteins that prevent immune cells penetrate.
Exposing the analysis of tumor tissue, the researchers from the United Kingdom found high levels of CXCR2 protein. The higher was the level of the patient, the worse the results were shown during treatment.
Further experiments in mice confirmed the assumption that the protective effect of CXCR2 protein to the tumor. In addition, the scientists found that mice deprived of CXCR2, immune cells infiltrated into the malignancy.
Further researchers combined blocking CXCR2 protein isolation with immunotherapy, particularly with the use of the drug gemcitabine. And get even more powerful response - T cells in large numbers entered into a cancerous tumor. Dr. Jennifer Morton says that it was the most important discovery, which increased the efficiency of immunotherapy and immune cells give access to tumors.
In addition, scientists have tried to understand why CXCR2 contributed to the development of tumors. They concluded that the protein plays a "guide" role for neutrophils and myeloid series of cells that should protect tissue from damage.
Apparently, malignancy somehow change their orientation and use for their growth. In support of this, researchers noted a large number of neutrophils and tumor suppressor cells in the tumor.
Professor Samson explains, "In the early development of the disease, neutrophils and myeloid cells are designed to stop the growth of tumors. Later, however, they, on the contrary, contribute to its growth." Thus, scientists still have a lot of work for the understanding of pancreatic cancer development mechanisms.
"The good news is that clinical trials CXCR2 protein blockers already come to an end Doctors are aware of their safety for patients and know how best to give them.", - says Dr. Jennifer Morton.
Based on materials medicalnewstoday.com